Morgan Stanley Reiterates Overweight on LifeStance Health Gr, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Ricky Goldwasser has reiterated an Overweight rating on LifeStance Health Gr (NASDAQ:LFST) and maintained a $10 price target.
July 13, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on LifeStance Health Gr, maintaining a $10 price target.
The Overweight rating from Morgan Stanley indicates a positive outlook for LifeStance Health Gr. The maintained price target of $10 suggests that the analyst believes the stock is undervalued at current levels. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100